Merrimack Pharmaceuticals (NASDAQ:MACK) : During the past 4 weeks, traders have been relatively bearish on Merrimack Pharmaceuticals (NASDAQ:MACK), hence the stock is down -12.49% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.02% relative to the S&P 500. The stock has risen by 1.26% in the past week indicating that the buyers are active at lower levels, but the stock is down -11.08% in the past 4 weeks.
The company shares have dropped -53.63% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $12.32 and the one year low was seen on Feb 24, 2016. The 50-Day Moving Average price is $6.25 and the 200 Day Moving Average price is recorded at $6.80.
The stock has recorded a 20-day Moving Average of 5.56% and the 50-Day Moving Average is 12.2%.
Merrimack Pharmaceuticals (NASDAQ:MACK): The stock was completely flat for the day, closing at $5.62 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $5.63, the stock touched an intraday high of $5.72 and a low of $5.57. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $5.62. The total trading volume on Friday was 1,289,070.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Merrimack Pharmaceuticals Inc, Porter Michael E had purchased shares worth of $36,000 in a transaction dated on March 17, 2016. A total of 5,000 shares were purchased at a price of $7.2 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Companys most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.